Identifying the molecular causes of vision loss in demyelinating disease

Demyelinating diseases, such as multiple sclerosis (MS), are frequently associated with the progressive loss of vision. The retinal nerve damage is thought to be caused by immune system-mediated inflammation; however, other demyelinating disorders, such as Pelizaeus-Merzbacher disease, do not involve the immune system, suggesting that there are other causes of retinal nerve damage.

Deimination is a protein modification that is altered in patients with MS and PMD. In this issue of the , researchers led by Sanjoy Bhattacharya at the University of Miami investigated the role of deimination in retinal in a mouse model of demyelinating disease (ND4 mice).

They found that deimination was reduced in patients with demyelinating diseases and in ND4 mice that exhibited vision loss. Decreases in deamination could be detected in the mice prior to the onset of other symptoms.

Bhattacharya and colleagues found that they could improve visual function in ND4 mice by restoring deimination. These results demonstrate that loss of deimination underlies nerve damage in and may be a suitable target for therapeutic intervention.

More information: Deimination restores inner retinal visual function in murine demyelinating disease, Journal of Clinical Investigation, doi:10.1172/JCI64811

add to favorites email to friend print save as pdf

Related Stories

Novel mouse model of demyelinating disorder

Jan 14, 2010

In the February 1st issue of G&D, Dr. Brian Popko (The University of Chicago) and colleagues describe how mutation of a gene called ZFP191 leads to disordered CNS myelination in mice -- reminiscent of what is seen in human ...

Anti-HIV drugs reduce the cause of some forms of vision loss

May 23, 2008

A potential new therapeutic use for anti-HIV drugs known as protease inhibitors has been suggested by a team of researchers from Harvard Medical School, Boston, and Inserm U848, France, as a result of their work in a mouse ...

Recommended for you

Multidose eye drop approach approved by joint commission

Dec 14, 2014

(HealthDay)—A policy and procedural approach to the use of multidose eye drops has been approved by The Joint Commission and can reduce costs for patients and facilities, according to an article published ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.